You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 27, 2024

Claims for Patent: 9,828,425

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,828,425

Title:	Anti-ILT5 antibodies and ILT5-binding antibody fragments
Abstract:	Disclosed herein are antibodies and ILT5-binding fragments thereof that specifically bind to ILT5, e.g., human ILT5 (hILT5), and pharmaceutical compositions comprising such ILT5-binding antibodies and ILT5-binding fragments thereof.
Inventor(s):	Apostolou; Irina (Norwell, MA), Ponath; Paul (San Francisco, CA), Ponte; Joe (Weymouth, MA), Rosenzweig; Michael (Boston, MA)
Assignee:	Merck Sharp & Dohme Corp. (Rahway, NJ)
Application Number:	14/644,229
Patent Claims:	1. A composition comprising an isolated antibody that binds immunoglobulin-like transcript 5 (ILT5) or an ILT5-binding fragment of the antibody comprising a heavy chain variable region comprising a heavy chain complementarity determining region 1 comprising the amino acid sequence of SEQ ID NO: 4, a heavy chain complementarity determining region 2 comprising the amino acid sequence of SEQ ID NO: 5, and a heavy chain complementarity determining region 3 comprising the amino acid sequence of SEQ ID NO: 6; and a light chain variable region comprising a light chain complementarity determining region 1 comprising the amino acid sequence of SEQ ID NO: 7, a light chain complementarity determining region 2 comprising the amino acid sequence of SEQ ID NO: 8, and a light chain complementarity determining region 3 comprising the amino acid sequence of SEQ ID NO: 9; and one or more chemotherapeutic agents. 2. The composition of claim 1 wherein the chemotherapeutic agent is an anti-metabolite, an agent that affects microtubule formation, an alkylating agent, a cytotoxic antibiotic, an anti-angiogenic agent, a biologic agent or an anti-CD3 antibody. 3. The composition of claim 1 wherein the chemotherapeutic agent is a nucleoside analogue. 4. The composition of claim 1 wherein the chemotherapeutic agent is aminopterin, methotrexate, pemetrexed, raltitrexed, cladribine, clofarabine, fludarabine, mercaptopurine, pentostatin, thioguanine, capecitabine, cytarabine, fluorouracil, floxuridine, gemcitabine, paclitaxel, docetaxel, vincristine, vinblastine, vindesine, vinorelbin, etoposide, teniposide, cyclophosphamide, doxorubicin, avastin, herceptin, otelixizumab or visilizumab. 5. The composition of claim 1 wherein the chemotherapeutic agent is a topoisomerase II inhibitor. 6. The composition of claim 1 wherein the chemotherapeutic agent is an anti-angiogenic agent. 7. The composition of claim 1 wherein the chemotherapeutic agent is a biological agent. 8. The composition of claim 1 wherein the chemotherapeutic agent is an alkylating agent. 9. The composition of claim 1 wherein the chemotherapeutic agent is a cytotoxic antibiotic. 10. The composition of claim 1 wherein the chemotherapeutic agent is an agent that affects microtubule formation. 11. The composition of claim 1 wherein the chemotherapeutic agent is paclitaxel. 12. The composition of claim 1 wherein the chemotherapeutic agent is docetaxel. 13. The composition of claim 1 wherein the chemotherapeutic agent is fluorouracil. 14. The composition of claim 1 wherein the chemotherapeutic agent is cyclophosphamide. 15. The composition of claim 1 wherein the chemotherapeutic agent is methotrexate. 16. The composition of claim 1 wherein the chemotherapeutic agent is vincristine. 17. The composition of claim 1 wherein the chemotherapeutic agent is vinblastine. 18. The composition of claim 1 wherein the chemotherapeutic agent is capecitabine. 19. The composition of claim 1 wherein the chemotherapeutic agent is doxorubicin. 20. The composition of claim 1 wherein the antibody or fragment comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO: 1 and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3.

Details for Patent 9,828,425

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998	⤷ Try a Trial	2030-01-20
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017	⤷ Try a Trial	2030-01-20
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004	⤷ Try a Trial	2030-01-20
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.